BrainStorm Cell Therapeutics Announces Nasdaq Delisting and Transition to OTCQB
The delisting is a result of the company's non-compliance with Nasdaq Listing Rule 5550(b)(1), pertaining to its minimum shareholder equity requirement.
BrainStorm has already secured approval for its common stock to be quoted on the OTCQB Venture Market, a U.S. trading platform operated by OTC Markets Group. The company anticipates its shares will begin trading on the OTCQB under the same symbol, BCLI, beginning at the open of trading on July 18, 2025, or as soon as possible thereafter.
Chaim Lebovits, CEO of BrainStorm Cell Therapeutics, stated, 'While this delisting from Nasdaq is a challenging outcome, we want to assure our shareholders and the patient community that it does not alter our core mission or our unwavering commitment to advancing NurOwn for ALS patients. Our pre-arranged transition to OTCQB ensures continuous trading for our shares and allows us to focus entirely on NurOwn's development. We remain fully dedicated to our ongoing scientific and clinical programs, including preparations for our pivotal Phase 3b trial under the Special Protocol Assessment (SPA) agreement with the FDA.'
The company confirms that the delisting does not impact its business operations, its ongoing research and development efforts, or its commitment to its shareholders. BrainStorm will continue to provide updates on its progress and financial status in compliance with applicable SEC regulations.
About NurOwn® The NurOwn® technology platform (autologous MSC-NTF cells) represents a promising investigational therapeutic approach to targeting disease pathways important in neurodegenerative disorders. MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo. MSCs are converted into MSC-NTF cells by growing them under patented conditions that induce the cells to secrete high levels of neurotrophic factors (NTFs). Autologous MSC-NTF cells are designed to effectively deliver multiple NTFs and immunomodulatory cytokines directly to the site of damage to elicit a desired biological effect and ultimately slow or stabilize disease progression.
About BrainStorm Cell Therapeutics Inc. BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) is a leading developer of autologous adult stem cell therapies for debilitating neurodegenerative diseases. The company's proprietary NurOwn® platform uses autologous mesenchymal stem cells (MSCs) to produce neurotrophic factor-secreting cells (MSC-NTF cells), designed to deliver targeted biological signals that modulate neuroinflammation and promote neuroprotection.
NurOwn® is BrainStorm's lead investigational therapy for amyotrophic lateral sclerosis (ALS) and has received Orphan Drug designation from both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). A Phase 3 trial in ALS (NCT03280056) has been completed, and a second Phase 3b trial is set to launch under a Special Protocol Assessment (SPA) agreement with the FDA. The NurOwn clinical program has generated valuable insights into ALS disease biology, including pharmacogenomic response associated with the UNC13A genotype, biomarker data collected at seven longitudinal time points, and a comprehensive analysis of the 'Floor Effect' – a critical challenge in measuring clinical outcomes in advanced ALS. BrainStorm has published its findings in multiple peer-reviewed journals. In addition to ALS, BrainStorm has completed a Phase 2 open-label multicenter trial (NCT03799718) of MSC-NTF cells in progressive multiple sclerosis (MS), supported by a grant from the National MS Society. BrainStorm is also advancing a proprietary, allogeneic exosome-based platform designed to deliver therapeutic proteins and nucleic acids. The company recently received a Notice of Allowance from the U.S. Patent and Trademark Office for a foundational patent covering its exosome technology, further strengthening BrainStorm's growing IP portfolio in this emerging area of regenerative medicine. To learn more, visit www.brainstorm-cell.com.
Notice Regarding Forward-Looking Statements This press release contains 'forward-looking statements' that are subject to substantial risks and uncertainties, including statements regarding meetings with the U.S. Food and Drug Administration (FDA), Special Protocol Assessment (SPA), the clinical development of NurOwn as a therapy for the treatment of ALS, the future availability of NurOwn to patients, and the future success of BrainStorm. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as 'anticipate,' 'believe,' 'contemplate,' 'could,' 'estimate,' 'expect,' 'intend,' 'seek,' 'may,' 'might,' 'plan,' 'potential,' 'predict,' 'project,' 'target,' 'aim,' 'should,' 'will' 'would,' or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on BrainStorm's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. These potential risks and uncertainties include, without limitation, management's ability to successfully achieve its goals, BrainStorm's ability to raise additional capital, BrainStorm's ability to continue as a going concern, prospects for future regulatory approval of NurOwn, whether BrainStorm's future interactions with the FDA will have productive outcomes, and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at http://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations, and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance, or achievements.
CONTACTS
Investors:Michael Wood Phone: +1 646-597-6983 mwood@lifesciadvisors.com
Media:Uri Yablonka, Chief Business Officer Phone: +1 917-284-2911 uri@brainstorm-cell.com
Logo – https://mma.prnewswire.com/media/1166536/BrainStorm_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/brainstorm-cell-therapeutics-announces-nasdaq-delisting-and-transition-to-otcqb-302508133.html
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
5 hours ago
- Malaysian Reserve
NEOG INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Neogen Corporation Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
SAN DIEGO, July 26, 2025 /PRNewswire/ — The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers of Neogen Corporation (NASDAQ: NEOG) common stock between January 5, 2023 and June 3, 2025, both dates inclusive (the 'Class Period'), have until September 16, 2025 to seek appointment as lead plaintiff of the Neogen class action lawsuit. Captioned Operating Engineers Construction Industry and Miscellaneous Pension Fund v. Neogen Corporation, No. 25-cv-00802 (W.D. Mich.), the Neogen class action lawsuit charges Neogen as well as certain of Neogen's top executives with violations of the Securities Exchange Act of 1934. If you suffered substantial losses and wish to serve as lead plaintiff of the Neogen class action lawsuit, please provide your information here: You can also contact attorneys J.C. Sanchez or Jennifer N. Caringal of Robbins Geller by calling 800/449-4900 or via e-mail at info@ CASE ALLEGATIONS: Neogen, together with its subsidiaries, engages in the development, manufacture, and marketing of various products and services dedicated to food and animal safety. According to the complaint, in December 2021, it was announced that Neogen would merge with the Food Safety Division of the 3M Company, with the deal closing in September 2022. The Neogen class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) defendants led investors to believe that Neogen's integration with 3M was progressing much better than it actually was; and (ii) even when Neogen was forced to reveal that certain 'inefficiencies' arose as a result of the integration, defendants downplayed them and assured investors that they were fully aware and committed to resolving them quickly. The Neogen class action lawsuit further alleges that on January 10, 2025, Neogen announced its preliminary second quarter of 2025 financial results, revealing, among other things, that: (i) GAAP net income in the quarter was significantly negative due to a $461 million non-cash goodwill impairment charge related to the 3M acquisition; (ii) Neogen cut its fiscal year 2025 revenue and EBITDA guidance; and (iii) Neogen concluded that, as of November 30, 2024, Neogen had material weaknesses in its internal control over financial reporting. On this news, the price of Neogen common stock fell more than 5%, according to the complaint. Then, on April 9, 2025, the Neogen class action lawsuit alleges that Neogen announced its third quarter of 2025 financial results, reporting a loss of $11 million, or $0.05 per share, compared with a loss of $2 million, or $0.01 per share, a year earlier. Neogen further announced that revenue fell 3.4% to $221 million which had been negatively impacted by integration issues, Neogen was cutting its fiscal year 2025 revenue and EBITDA outlook, capital expenditures were expected to be $100 million as a result of lowered adjusted EBITDA and a 'pull-forward of . . . integration capex into fiscal 2025,' and that CEO, defendant John Adent, would be stepping down. On this news, the price of Neogen common stock fell 28%, according to the complaint. Finally, on June 4, 2025, Neogen revealed that it expected 'EBITDA margin to probably be around the high-teens' which represented a considerable drop from the previous quarter's profit margin of 22%, blaming the expected shortfall on 'elevated . . . inventory write-offs,' according to the complaint. The Neogen class action lawsuit alleges that on this news, the price of Neogen common stock fell more than 17%. THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased Neogen common stock during the Class Period to seek appointment as lead plaintiff in the Neogen class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Neogen class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Neogen class action lawsuit. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Neogen class action lawsuit. ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world's leading law firms representing investors in securities fraud and shareholder litigation. Our Firm has been ranked #1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors. In 2024, we recovered over $2.5 billion for investors in securities-related class action cases – more than the next five law firms combined, according to ISS. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world, and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information: Past results do not guarantee future outcomes. Services may be performed by attorneys in any of our offices. Contact: Robbins Geller Rudman & Dowd LLPJ.C. Sanchez, Jennifer N. Caringal655 W. Broadway, Suite 1900, San Diego, CA 92101800-449-4900info@
The Sun
7 hours ago
- The Sun
VinFast Indonesia continues to expand nationwide service workshop network
JAKARTA, INDONESIA - Media OutReach Newswire - 26 July 2025 - VinFast, the Vietnamese Nasdaq-listed pure-electric vehicle manufacturer, today announced the signing and implementation of strategic cooperation agreements with leading Indonesian service workshop partners. This strategic move significantly expands VinFast's after-sales network, demonstrating its commitment to providing maximum convenience for customers transitioning to electric vehicles. During the Gaikindo Indonesia International Auto Show (GIIAS) 2025, open to the public from July 24 to August 3, VinFast signed Memoranda of Understanding (MOUs) with three new strategic partners: Nawilis, Warna Warni Ban, and Raperind. These partnerships further strengthen the Company's continuously expanding genuine service network in Indonesia. Specifically, 9 Nawilis workshops will become VinFast's authorized genuine service centers, all classified as Level 1 workshops. Other partners, Warna Warni Ban (5 Level 1 workshops) and Raperind (5 workshops, including 2 Level 1 and 3 Level 2 workshops), also join the system, enriching VinFast's service network across Indonesia. These third-party authorized service workshops will be clearly categorized by their scope of expertise, ensuring Indonesian customers consistently receive appropriate and professional services. Level 1 workshops are authorized to provide a full range of essential services, including maintenance, basic repairs, basic warranty handling, software updates, and diagnostic checks for VinFast EVs. Meanwhile, Level 2 workshops will focus on core services such as periodic maintenance, basic repairs, and basic warranty services, ensuring VinFast customers receive optimal service at every touchpoint throughout their EV ownership journey. These new partners complement the list of strategic partners with whom VinFast previously finalized agreements, including Otoklix and Bengkel BOS. Otoklix has added 150 workshops to VinFast's network, comprising 41 Level 1 and 109 Level 2 workshops. Bengkel BOS has also contributed 12 Level 1 workshops. As a result, VinFast has built a nationwide network of 181 authorized genuine service workshops, including a total of 69 Level 1 and 112 Level 2 workshops. All Indonesian service workshops will meet VinFast's stringent standards for facilities, machinery and equipment, and personnel qualifications. These partners will also provide genuine services and parts for VinFast car owners, contributing to maximum convenience and peace of mind. Throughout the cooperation, VinFast will actively support personnel training and technical consultation to help partners rapidly expand their authorized service workshop systems, especially as VinFast's product range in Indonesia continues to grow, and the number of vehicle deliveries is expected to increase significantly. Mr. Chrisdavin Teng, Director of Warna Warni Ban commented, 'We are thrilled to become an authorized provider of genuine services for VinFast electric vehicles in Indonesia. We believe in VinFast's growth potential in Southeast Asia. Together, VinFast and we aim to provide consumers with excellent experiences and drive the continuously growing electric vehicle market.' Mr. Kariyanto Hardjosoemarto, CEO of VinFast Indonesia, shared, 'The continuous expansion of our service workshop network once again reaffirms VinFast's strong and consistent commitment to providing comprehensive, convenient, and high-quality after-sales service, ensuring Indonesian customers can confidently enjoy the superior value of the VinFast electric vehicle experience. This strategy not only helps us expand our customer reach but also optimizes operational efficiency during our expansion in Indonesia.' VinFast is strengthening its after-sales network as its product range in the Indonesian market continues to expand. In just over a year since officially entering the market, VinFast has rapidly introduced a diverse product range across the most popular segments in Indonesia, from the VF 3, VF 5, VF 6 to the VF e34, and most recently, the VF 7. These products are all offered with exceptionally attractive sales and after-sales policies, such as free charging at V-GREEN charging stations and 0% interest financing support for vehicle purchases. Simultaneously, VinFast is continuously fostering cooperation with dealership and banking partners, making it easier for customers to access, own, and use green transportation.
The Sun
7 hours ago
- The Sun
VinFast Indonesia to expand dealership network to 85 showrooms nationwide
JAKARTA, INDONESIA - Media OutReach Newswire - 26 July 2025 - VinFast, the Vietnamese Nasdaq-listed EV manufacturer, has officially signed agreements with 20 new dealership partners during the Gaikindo Indonesia International Auto Show (GIIAS) 2025. These agreements will bring VinFast closer to its goal of operating 100 dealership showrooms this year. This marks a strategic advancement for VinFast in its journey to conquer the Indonesian market, and underscores its commitment to delivering superior products and services to consumers across the archipelago. The 20 new VinFast dealership partners are highly reputable and capable enterprises in Indonesia's automotive sector. They include PT Auto Green AAS, PT Ivan Dijaja Mandiri, PT Bimmeroom Mobil Indonesia, PT Alto Anugerah Abadi, PT Prestisius Indonesia, and PT Mega Central Autoniaga, etc. Each partner was meticulously selected based on their strong market position and extensive experience in strategic regions. According to the signed dealer agreements and Memoranda of Understanding, the 20 new dealerships are expected to operate a total of 38 VinFast showrooms, which will progressively become operational from the time of signing until the end of 2026. Meanwhile, existing dealerships will open an additional 23 showrooms, bringing the total number of dealerships in VinFast's retail network in Indonesia to 34 dealerships and expected 85 showrooms. The strategic collaboration with these trusted partners is expected to significantly accelerate VinFast's expansion, swiftly establishing a comprehensive distribution and service network across Indonesia's key regions, expanding VinFast's presence to 19 provinces and 41 cities in Indonesia. This move aims to ensure VinFast's smart EVs are readily accessible to a broad spectrum of Indonesian consumers, while simultaneously reinforcing an international-standard after-sales service system in pivotal population centers. Throughout the entire cooperation process, VinFast is committed to providing maximum support to its authorized dealers. This includes implementing comprehensive and continuous training programs for dealership personnel, equipping them with solid professional knowledge about products, technology, and maintenance and repair procedures in accordance with VinFast's global standards. Mr. Ivan Farrel Djayaprawira, Director of PT Ivan Djaja Mandiri, stated: 'As a strategic partner of VinFast, we are proud to contribute modern infrastructure, superior capabilities, established reputation, and deep understanding of the Indonesian market. Joining VinFast in its journey to accelerate the global green revolution, we have strong confidence in the explosive potential of electric vehicles and VinFast's prospects here. We are committed to creating optimal value for a mutually beneficial partnership, thereby delivering top-quality electric vehicle products and services that best meet customer needs.' Mr. Kariyanto Hardjosoemarto, CEO of VinFast Indonesia, shared: 'With VinFast's comprehensive support for our dealership partners, we are committed to ensuring that every customer in Indonesia will always experience professional consulting services and outstanding after-sales policies, providing absolute peace of mind when purchasing and owning a vehicle. In the spirit of this strong cooperation, VinFast and our dealership network will unite to work towards the goal of creating a green mobility future for Indonesia, actively contributing to the nation's EV development roadmap and delivering practical, meaningful value to society.' VinFast is accelerating its retail network expansion amidst a continuously growing range of products in the Indonesian market. In just over a year since officially entering the market, VinFast has swiftly introduced a diverse product lineup covering the most popular segments, from the VF 3, VF 5, VF 6 to the VF e34, and most recently, the VF 7. These products are all offered with exceptionally attractive sales and after-sales policies, such as complimentary charging at V-GREEN charging stations and 0% interest financing support for vehicle purchases. Simultaneously, VinFast continues to foster partnerships with after-sales service providers, workshops, and banks, maximizing convenience for Indonesian consumers transitioning to green mobility.
